There are differences between cost effectiveness and affordability that people don't always understand. A drug may be cost effective but still not fall within the budget, explained Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
There are differences between cost effectiveness and affordability that people don't always understand. A drug may be cost effective but still not fall within the budget, explained Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
Transcript (slightly modified)
How do cost effectiveness and affordability differ in ways people might not understand?
Cost effectiveness is normally measured as the cost per unit of health gain, like cost per quality-adjusted life years (QALY), so it is a ratio. The inverse of that ratio is a measure of value for money—health gain for a dollar spent. There is sometimes the use of cost effectiveness to compare that to some notion of what is a reasonable amount to spend to buy a life year.
In the US, we use numbers like $100,000 per QALY $150,000 per QALY; in the UK, they use £25,000 per QALY. Sometimes when somebody says a drug is cost effective, what they mean is that at that price, it comes within that threshold. So, the cost per QALY gained, given the cost at the price, is within that reasonable threshold.
Now, you can have a new product that meets that cost effectiveness threshold, but the total cost of paying for all of the patients who might be eligible, breaks the budget. Meaning that the payer went over on the budget and that gives rise to an affordability question. Given that the drug meets the cost effectiveness threshold—can the payer afford to pay for it? The poster child for that is Sovaldi hepatitis C drugs, where both the price was high and the volume was high. So, the payers encountered the question of: can we afford to pay for everybody, for whom the drug is cost effective, and still come within budget?
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More